A fixed-dose combination of ledipasvir and sofosbuvir was an effective treatment for HIV patients co-infected with HCV genotype 1 or 4, according to a study published in New England Journal of Medicine.
Here are seven insights:
1. The study included 335 patients.
2. All patients received ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks.
3. Overall, 322 patients — 96 percent — had a sustained virologic response at 12 weeks after the end of therapy.
4. Rates of sustained virologic response were similar regardless of previous treatment or the presence of cirrhosis.
5. Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the end of treatment.
6. The most common adverse events were headache (25 percent), fatigue (21 percent) and diarrhea (11 percent).
7. No patient discontinued treatment because of adverse events.